Ipca Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
November 10, 2023 at 03:06 am EST
Share
Ipca Laboratories Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was INR 20,339.6 million compared to INR 16,009.5 million a year ago. Revenue was INR 20,725.1 million compared to INR 16,371.8 million a year ago. Net income was INR 1,450.6 million compared to INR 1,439 million a year ago. Basic earnings per share from continuing operations was INR 5.72 compared to INR 5.67 a year ago. Diluted earnings per share from continuing operations was INR 5.72 compared to INR 5.67 a year ago.
For the six months, sales was INR 36,191.7 million compared to INR 31,866.9 million a year ago. Revenue was INR 37,025.7 million compared to INR 32,450.3 million a year ago. Net income was INR 3,078.8 million compared to INR 2,869.6 million a year ago. Basic earnings per share from continuing operations was INR 12.14 compared to INR 11.31 a year ago. Diluted earnings per share from continuing operations was INR 12.14 compared to INR 11.31 a year ago.
Ipca Laboratories Limited is an India-based pharmaceutical company. The Company is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIâs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.
IPCA LABORATORIES LIMITED 
